Chemoenzymatic Defucosylation of Therapeutic Antibodies for Enhanced Effector Functions Using Bacterial α-Fucosidases.
Sign Up to like & getrecommendations! Published in 2018 at "Methods in molecular biology"
DOI: 10.1007/978-1-4939-8648-4_19
Abstract: Core fucosylation plays a critical role in modulating the effector functions of therapeutic antibodies such as the antibody-dependent cellular cytotoxicity (ADCC) through adversely affecting the affinity of antibodies for Fcγ receptors. Thus, a facile method… read more here.
Keywords: therapeutic antibodies; bacterial fucosidases; herceptin; effector functions ... See more keywords
Cost minimization analysis of Herceptin subcutaneous versus Herceptin intravenous treatment for patients with HER2+ Breast cancer in Greece
Sign Up to like & getrecommendations! Published in 2017 at "Journal of cancer policy"
DOI: 10.1016/j.jcpo.2017.05.001
Abstract: Abstract Aim To conduct an economic evaluation comparing Herceptin subcutaneous formulation (Herceptin-SC) with Herceptin intravenous formulation (Herceptin-IV), in the treatment of patients with human epidermal growth factor receptor 2-positive (HER2+) early and metastatic breast cancer… read more here.
Keywords: herceptin subcutaneous; herceptin; herceptin herceptin; treatment ... See more keywords
Abstract LB024: Pharmacokinetics of a novel viscoelastic suspension of trastuzumab biosimilar for high-concentration, low-volume subcutaneous injection
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb024
Abstract: Background: Xeris Pharmaceuticals (Chicago, IL, USA) has developed the proprietary XeriJect® technology, which uses a novel viscoelastic suspension for delivery of high-concentration, low-volume subcutaneous (SC) injections of therapeutic antibodies. Trastuzumab (TmAb) is a monoclonal antibody… read more here.
Keywords: injection; xeriject tmab; herceptin; high concentration ... See more keywords
Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving surgery
Sign Up to like & getrecommendations! Published in 2019 at "Theranostics"
DOI: 10.7150/thno.36514
Abstract: A high risk of local relapse is the main challenge of HER2+ breast cancer after breast-conserving surgery. We aimed to develop a long-acting delivery system for Herceptin, a HER2-targeting antibody, using injectable and thermosensitive hydrogels… read more here.
Keywords: breast conserving; her2 breast; herceptin; breast ... See more keywords